Sie sind hier: Skip Navigation LinksUniversitäres Krebszentrum Leipzig

Details zur Studie TroFuse-011

Kurzname

TroFuse-011

Studientitel
A Phase 3, Randomized, Open-label Study Comparing Efficacy and Safety of Sacituzumab Tirumotecan (sac-TMT, MK-2870) as a Monotherapy and in Combination with Pembrolizumab (MK-3475) Versus Treatment of Physician's Choice in Participants With Previously Untreated Locally Recurrent Unresectable or Metastatic Triple-Negative Breast Cancer Expressing PD-L1 at CPS Less than 10 (TroFuse-011)
Diagnosegruppen

Mamma

Linie

Erstlinie

Phase

Phase 3

Fachbereich
Gyn.-/ Brustzentrum
Standorte
Leipzig
Studienstatus
initiiert (rekrutierend)
Ansprechpartner:in
Samira Michel
Telefon
0341-97-23260
Prüfer:in
Aktas, Prof. Dr. med.
Studienregister
Liebigstr. 22, Haus 7
04103 Leipzig
Termine:
0341 - 97 17365
Sekretariat:
0341 - 97 12560
Fax:
0341 - 97 17049
Map
7nach oben